Although the EGFP+ tumor cells displayed robust mTOR phosphorylation, the mTOR inhibitor, rapamycin, did not strongly affect the CSC-associated CD24 and CD44 markers (data not shown). This evidence concerns the gene CD24 and neoplasm.